Advancing health: Our impactful R&D investments

Improving the health and lives of humans and animals is our primary mission as a research-driven biopharmaceutical company. At Boehringer Ingelheim, we focus on developing innovative therapies that can enhance and extend lives. Our commitment to research & development (R&D) and scientific innovation is unwavering, with a total investment of more than 5 billion EUR in 2022.

Of this total amount, 91% (ca. 4.6 billion EUR) was dedicated to human pharma, with a focus on six priority areas: Cardio-Renal-Metabolic, Oncology, Respiratory, Immunology, Mental Health, and Retinal Diseases. Over half of this budget (2.5 billion EUR) was spent on clinical development, primarily in phase 2 and 3 trials, where we rigorously test the most promising and innovative medicines and therapeutic vaccines. Our human pharma R&D efforts align closely with the Access to Medicine Foundation’s priorities in the areas of cancers and other non-communicable diseases.

For animal health, we invested 9% (ca. 0.4 billion EUR) in R&D+Medicine, addressing infectious and non-infectious diseases, parasitology, and veterinary public health. These strategic investments are driven by our vision to create a more sustainable and healthier world for both humans and animals. For more information, visit our Human Pharma Clinical Pipeline and our Annual Report from 2022 (see below).